ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Case Report

Case Report: Exploratory treatment with multiple intravenous infusion of the autologous adipose tissue-derived mesenchymal stem cells for the treatment of Diamond-Blackfan anemia patient

[version 1; peer review: 1 approved with reservations]
PUBLISHED 13 Sep 2019
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

Abstract

Diamond-Blackfan anemia (DBA) is a rare congenital erythropoietic disorder characterized by erythroblastopenia. Conventional treatments of DBA are the administrations of corticosteroids and blood transfusions for mitigation of anemia, and bone marrow transplantation. However, there are hurdles to overcome for long-term use and the conventional treatment. Mesenchymal stem cells (MSCs) have been noted as a novel alternative cell therapy in various diseases, and adipose tissue-derived MSCs (AdMSCs) are known for their versatile efficacies and feasibility. Here, we report the potential efficacies and the safety of intravenous administration of the autologous AdMSC in a patient with DBA for the first time. The isolation and characterization of autologous AdMSCs from a girl aged 11 years, 10 months with DBA were carried out due to the mutation of ribosomal protein s24 (RPS24). AdMSCs, diluted to 1 x 10cells in 100 ml of saline, were infused intravenously for 1 hour. Intravenous administration of AdMSCs was carried out 5 times in 2-week intervals, and the patient was checked using various assessments (vital signs, physical examination, laboratory tests, adverse events, etc) at every visit. After 3, 6 and 9 months from the first administration of AdMSCs, red blood cell (RBC) count, hemoglobin value, and hematocrit were assessed for the efficacy. There were no side effects or adverse events observed during the treatment. Although showing subnormal values, the RBC number, hemoglobin level, and hematocrit were improved 9 months after the systemic administration of AdMSCs from baseline; the RBC count (x10/μl), hemoglobin level (g/dl) and hematocrit level (%) were increased from 1.58 to 2.38, 5.6 to 8.3, and 16.9 to 26.1, respectively. The present case reported the first AdMSC administration for DBA patient and indicates it is possible that the intravenous administration of autologous AdMSC can be a safe alternative for DBA treatment.

Keywords

Diamond-Blackfan anemia, adipose tissue-derived mesenchymal stem cell, intravenous injection

Introduction

Diamond-Blackfan anemia (DBA) is a rare congenital bone marrow disorder, which characterized by erythroblastopenia1. The symptoms of DBA are generally presented in infancy, with broad congenital abnormality including growth retardation, defect of heart and urogenital system, malformation of hands, and cleft lip/palate2. It has been known that a mutation in the genes coding ribosomal proteins (RP) is responsible for DBA2. The large proportion of DBA patients have mutations detected in RP genes of the small (RPS7, RPS10, RPS15A, RPS17, RPS19, RPS24, RPS26, RPS27, RPS28, RPS29) or the large (RPL5, RPL11, RPL15, RPL18, RPL26, RPL27, RPL31, RPL35, RPL35A) ribosomal subunit3. In rare cases of DBA, two pathogenic X-linked mutations (GATA1, TSR2) were reported recently2. These ribosomal abnormalities in DBA are known to lead to the impairment of erythropoiesis4.

The treatment of DBA has conventionally focused on the mitigation of anemia resulting from impaired erythropoiesis. The administration of corticosteroids and blood transfusions have been commonly adopted for DBA patients2. However, steroids have various adverse effects after long-term use and the life-long transfusions for the patients who do not respond to steroids can also lead to problems, such as iron accumulation3. Allogenic hematopoietic stem cell (HSC) transplantation is considered a more fundamental approach for the steroid-refractory patients and to avoid iron accumulation from long-term transfusion5. Currently, the bone marrow from HLA-matching donors or cord blood transplantation have been carried out, and the positive outcomes have been reported6. However, allogenic HSC transplantation has considerable difficulties, such as the recruiting of HLA-matching donors, the in vitro propagation of HSCs, and the various complications from immunosuppression therapy, graft versus host disease (GVHD) etc.3.

Mesenchymal stem cells (MSCs) have been noted for a novel alternative in cell therapy in various diseases over past decades7,8. MSCs have been known for the effective tissue repair, angiogenesis, and the stimulation/mobilization of endogenous stem cells911. Adipose tissue-derived MSCs (AdMSCs) have shown several advantages over MSCs from other origins in safety and effectiveness, including a less invasive sampling procedure, abundant cell populations from tissue harvested and high capacity of proliferation12,13. Here we assessed the potential efficacies and the safety of intravenous administration of autologous AdMSCs in patients with DBA for the first time.

Case presentation

A girl aged 11 years and 10 months was admitted to our hospital (Bethesda Hospital, Yangsan, Korea). She presented with severe anemia, left blepharoptosis, and polydactylism in the right thumb at birth, and was diagnosed with pure red cell aplasia and congenital dyserythropoietic anemia in infancy. After seven transfusions in the first year of life, prednisolone or methylprednisolone were orally administrated at 1 mg/kg/day for 4 years from the age of 2.5 years. The patient was finally diagnosed with DBA due to a mutation in RPS24 at the age of 8 years by genetic analysis. The immediate family history was not identified. At that time of the visiting of the hospital for the treatment of AdMSC, the patient had already undergone four surgeries on her left blepharoptosis and had mild ptosis of the right eye; polydactylism in right hands was corrected after the surgery. The administration of autologous AdMSCs for DBA was approved by the Korean Ministry of Food and Drug Safety with Investigational New Drug Application for Emergency Use (Approval No. 20180101335). Written informed consent was acquired from the patient and patient’s parents before the initiation of treatment. This study was conducted in compliance with the Helsinki declaration and approved by Institutional Review Board of Bethesda Hospital (Approval No. 2018-FEB01).

The isolation and characterization of the autologous AdMSCs were performed using the previously established culture protocol14 under good manufacturing practice (GMP) conditions in the Stem Cell Research Institute of R Bio (Seoul, Republic of Korea). Briefly, the abdominal subcutaneous adipose tissue was obtained through liposuction, and digested with collagenase I (Gibco/Life Technologies, Grand Island, NY, USA). After centrifugation, the pellet was resuspended in DMEM (Invitrogen, Carlsbad, CA, USA)-based media containing 0.2 mM ascorbic acid and 10% fetal bovine serum (FBS; JR Scientific, Woodland, CA, USA). The cell fraction was cultured overnight at 37°C/5% CO2, and the cell adhesion was checked after 24 h. The cells were maintained for 4 to 5 days until confluent (passage 0). When the cells reached 90% confluency, they were subculture expanded in keratinocyte SFM-based media (Invitrogen, USA) containing 0.2 mM ascorbic acid, 0.09 mM calcium, 5 ng/ml rEGF, and 5% FBS until passage 3. Before transporting the cells for administration, aliquots of the AdMSCs are tested for cell viability, fungal, bacterial, endotoxin, and mycoplasma contamination and immunophenotype for MSCs. Cell viability evaluated by trypan blue exclusion was >91%, and no evidence of bacterial, fungal and mycoplasmal contamination was observed. The AdMSCs showed a homogenous population of cells with high positive marker expression levels of CD73 and CD90 at a high level of >85% and >99%, respectively. Negative markers of CD31, CD34, and CD45 were expressed at a very low level of <0.6%. AdMSCs finally adjusted to 1 × 108 cells in 100 ml of saline were injected intravenously for 1 hour. The intravenous administrations of AdMSC were carried out five times in 2-week intervals (June 21–Aug. 14, 2018), and the patient was instructed to visit the hospital to check the various assessments for safety (vital signs, physical examination, laboratory tests, adverse events, and serious adverse events).

The treatment schedule is showed in Figure 1. After 3 and 6 months from the first administration of AdMSCs, red blood cell (RBC) count, the hemoglobin value, hematocrit, reticulocyte percentage were assessed for the efficacy (Table 1).

e940cee6-eb42-44b9-8bd9-8b832f9d4f1e_figure1.gif

Figure 1. Treatment scheme of the of Adipose tissue-derived mesenchymal stem cell administration.

IV, intravenous; F/U, Follow-up; M, months; W, weeks.

Table 1. The clinical features of DBA patient: pre- and post-treatment of the administration of adipose tissue-derived mesenchymal stem cells.

PretreatmentPost-treatmentReference
Interval
BaselineMonth 3Month 6Month 9
Height (cm)151.4154.4155.3151.7*
Weight (kg)50.050.950.243.7*
RBC (×106/μl)1.581.812.152.385.7-8.8
Hemoglobin (g/dl)5.66.47.58.312.0-18.0
Hematocrit (%)16.919.222.926.137.1-57.0
WBC (×103/μl)5.16.65.75.96.0-19.5
Reticulocyte (%)1.31.61.90.5-2.5

* The 2017 Korean National Growth Charts for children and adolescents

There were no side effects or adverse events observed during the administration of the autologous AdMSC. Most criteria of the assessment for the vital signs, physical examination, and laboratory tests showed the values within normal or clinically meaningless subnormal range. There was also no concomitant medication during the treatment of AdMSC. Although showing subnormal values, the number of RBC, hemoglobin level, and hematocrit level were improved after the systemic administration of AdMSC. The patient showed steady improvement in anemia after the treatment of AdMSCs; the RBC count was 2.38 ×106/μl hemoglobin level was 8.3 g/dl and hematocrit level was 26.1% after 9 months from the first administration of AdMSC (Table 1).

Discussion

DBA is a congenital hematopoietic disorder caused by the mutation in genes of the ribosomal protein1. The mutation of RPS19 is founded in the approximate 25% of DBA cases, and RPS24 in 2% of cases1,4,15. The defects of RPS19, PRS24, and other genes involved in ribosomal biogenesis result in the impairment of the cell cycle and the protein synthesis rather than the differentiation process of the erythropoiesis, and finally give rise to the depletion of the erythrogenic progenitors16,17. Recently, gene therapy has been recommended as an emerging treatment, which could remedy the shortcomings of conventional treatment and be the fundamental cure3. However, the collection of genetically reprogrammed cells (induced pluripotent stem cells, HSCs, adult fibroblast, etc.) shows very low efficiency, and the risk of mutation limits the collecting of the clinical data and the application of treatment of humans3,4. AdMSCs, with its feasibility of the application, has already been identified as having potential for the treatment of various diseases, from chronic degenerative conditions to congenital defects or orphan diseases14,18. Autologous MSCs from patients with genetically defective disease could alleviate the patients’ own condition. The previous studies demonstrated that the autologous MSC from the patients with sickle cell anemia19 and autosomal dominant polycystic kidney disease20 were functionally compatible, and could be effective in the patients’ own status. The mechanisms of these efficacies of MSC are known to largely depend on the paracrine activity, which secretes the extracellular vesicles (exosomes) containing various cytokines, miRNAs, growth factors, and endocrine factors involving the bone regeneration, angiogenesis, immunomodulation, cellular proliferation, differentiation, recruiting of the endogenous stem cells21,22. Although the parameters were still in the subnormal range in the present case, the patient with DBA, who presented with severe anemia, showed a stable improvement from the anemic state after the intravenous administration of AdMSCs, without any other medications. The erythroid cells from patients with DBA have been reported to show defective expansion and proliferative properties23. However, the DBA erythroid colony formation could be enhanced under the presence of the exogenous stem cell factor (SCF, a KIT ligand) in vitro2325. SCF is a major hematopoietic factor; the stromal cells from patients with DBA normally express SCF mRNA transcripts26. SCF secreted from the arterial endothelial cell in the bone marrow is essential for the intrinsic HSC27. AdMSCs have superb angiogenetic properties, which are considered to secrete the exosomes containing SCF, colony stimulating factor, interleukins and the other hematopoietic factors18,27,28. Further, AdMSCs stimulate the regeneration of endothelial cells through the paracrine angiogenetic factors, such as vascular endothelial growth factor, basic fibroblast growth factor, etc.22. In this regard, the encouraging outcomes in the present case can be assumed that there would be the direct hematopoietic supports from the patient’s own AdMSCs, and/or indirect hematopoietic help from the endothelial cells induced by the patient’ own AdMSCs. However, due to the restrictive case number, the lack of assessment of the extent of angiogenesis and the hematopoietic analysis after treatment with AdMSCs, there is a limitation to evaluate the potential of AdMSCs for erythropoiesis. Nonetheless, the present case report dealt on the first patient’ own AdMSCs administration for DBA treatment and gave the possibility that the intravenous administration of autologous AdMSCs can be a safe alternative for DBA patients.

Data availability

All data underlying the results are available as part of the article and no additional source data are required.

Consent

Written informed consent for publication of the patients’ clinical details was obtained from the parents of the patient.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 13 Sep 2019
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Ra JC, Park JI and Yang PS. Case Report: Exploratory treatment with multiple intravenous infusion of the autologous adipose tissue-derived mesenchymal stem cells for the treatment of Diamond-Blackfan anemia patient [version 1; peer review: 1 approved with reservations]. F1000Research 2019, 8:1638 (https://doi.org/10.12688/f1000research.20391.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 13 Sep 2019
Views
7
Cite
Reviewer Report 16 Nov 2021
Seth J Corey, Department of Pediatric Hematology/Oncology and Stem Cell Transplantation, Cleveland Clinic, Cleveland, OH, USA 
Approved with Reservations
VIEWS 7
In this manuscript, the investigator report on the use of autologous mesenchymal stem cells for treatment of Diamond-Blackfan anemia. Following no preparative regimen and without any concomitant medication, 5 infusions of cultured adipocyte-derived MSC resulted in hemoglobin rise from 5.6 to 8.3 at ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Corey SJ. Reviewer Report For: Case Report: Exploratory treatment with multiple intravenous infusion of the autologous adipose tissue-derived mesenchymal stem cells for the treatment of Diamond-Blackfan anemia patient [version 1; peer review: 1 approved with reservations]. F1000Research 2019, 8:1638 (https://doi.org/10.5256/f1000research.22410.r98371)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 13 Sep 2019
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.